Clinical trial Recruiting at 1 site Phase 3 Interventional Ages 50 to 100

Effects of Ripasudil on Patients with Fuchs' Endothelial Dystrophy Undergoing Cataract Surgery

Official title: The Effects of Ripasudil in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Femtosecond Laser Assisted Cataract Surgery

Run by Singapore Eye Research Institute · NCT06048380 · Data updated 2026-11-12

This study is testing if a new eye drop called ripasudil can help people with Fuchs' Endothelial Dystrophy have better results after cataract surgery.

More Cataract trials

Quick facts

PhasePhase 3
Study typeInterventional
Ages50 Years to 100 Years
SexAll
Enrollment120 (estimated)
SponsorSingapore Eye Research Institute
Academic / other
Locations1 site (Singapore, Singapore)
StatusRecruiting
StartedMarch 1, 2025
Main results expectedJuly 2025
Study endsJuly 2025
Registry record updatedJanuary 29, 2025
Trial IDNCT06048380 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are patients over 50 years old diagnosed with Fuchs' Endothelial Dystrophy who are scheduled for cataract surgery.

Probably not a fit

Patients with only one functioning eye or those with other significant eye diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the impact of ripasudil, an ophthalmic solution, on patients with Fuchs' Endothelial Dystrophy (FED) who are undergoing femtosecond laser-assisted cataract surgery. Participants will be randomly assigned to receive either ripasudil or a placebo, allowing researchers to evaluate the clinical outcomes and identify which patients benefit most from the treatment. The study also aims to monitor any adverse effects associated with ripasudil administration. By analyzing pre-operative parameters, the trial seeks to enhance understanding of patient characteristics that predict treatment success.

Why it matters

Potential benefit: If successful, this treatment could improve corneal endothelial function and reduce cell loss after cataract surgery in patients with FED.

How similar studies have gone: While the use of ROCK inhibitors like ripasudil is promising, this specific application in FED patients undergoing cataract surgery is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patients with FED who will be listed for cataract surgery as part of standard clinical practice (A cataract will be defined as clouding of the lens that interferes with normal vision).
2. Only patients older than 50 years will be included, as cataracts develops with increasing age. No gender criteria are applied.
3. Ability to provide informed consent, and are willing and able to sign a written Informed Consent Form prior to any study-specific procedures.
4. Patients must be willing and able to return for scheduled follow-up examinations for up to 12 months after the surgery.

Exclusion Criteria:

1. Patients who are unable to give consent.
2. An only-functioning eye in a patient who has lost visual potential in the contralateral eye.
3. Diagnosis of clinically relevant eye diseases that may interfere with the aim of the study.
4. History of ripasudil use, as well as other systemic disease such as cardiovascular or renal disease.
5. Patients who have previous allergic reactions to the contents present in Glanatec Ophthalmic solution 0.4%

Where it's running

  • Singapore National Eye Centre
    Singapore, Singapore, Singapore
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.